請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/48140
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張美惠(Mei-Hwei Chang) | |
dc.contributor.author | Yu-Cheng Lin | en |
dc.contributor.author | 林裕誠 | zh_TW |
dc.date.accessioned | 2021-06-15T06:47:10Z | - |
dc.date.available | 2013-10-07 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-06-13 | |
dc.identifier.citation | Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005 Jul;129(1):113-21.
Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008 Oct;135(4):1176-84. Ambros V. The functions of animal microRNAs. Nature. 2004 Sep 16;431(7006):350-5. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol. 2004 Dec;41(6):943-9. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007 Apr;45(4):846-54. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002 Feb;17 Suppl:S186-90. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005 Feb;11(2):191-8. Atsuta Y, Ito LS, Oba-Shinjo SM, Uno M, Shinjo SK, Marie SK, Goto Y, Hamajima N. Associations of TNF-A-1031TT and -857TT genotypes with Helicobacter pylori seropositivity and gastric atrophy among Japanese Brazilians. Int J Clin Oncol. 2006 Apr;11(2):140-5. Bahl M, Qayyum A, Westphalen AC, Noworolski SM, Chu PW, Ferrell L, Tien PC, Bass NM, Merriman RB. Liver steatosis: investigation of opposed-phase T1-weighted liver MR signal intensity loss and visceral fat measurement as biomarkers. Radiology. 2008 Oct;249(1):160-6. Ball GD, Ambler KA, Chanoine JP. Pediatric weight management programs in Canada: Where, What and How? Int J Pediatr Obes. 2010 Aug 30. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16093-8. Barroso I, Luan J, Sandhu MS, Franks PW, Crowley V, Schafer AJ, O'Rahilly S, Wareham NJ. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia. 2006 Mar;49(3):501-5. Basantani MK, Sitnick MT, Cai L, Brenner DS, Gardner NP, Li JZ, Schoiswohl G, Yang K, Kumari M, Gross RW, Zechner R, Kershaw EE. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res. 2011 Feb;52(2):318-29. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006 Nov 30;355(22):2297-307. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8170-4. Bhalla S, Ozalp C, Fang S, Xiang L, Kemper JK. Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha. Functional implications in hepatic cholesterol and glucose metabolism. J Biol Chem. 2004 Oct 22;279(43):45139-47. Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005 May;25(5):1045-50. Breimer LH, Spyropolous KA, Winder AF, Mikhailidis DP, Hamilton G. Is bilirubin protective against coronary artery disease? Clin Chem. 1994 Oct;40(10):1987-8. Brouwers MC, Cantor RM, Kono N, Yoon JL, van der Kallen CJ, Bilderbeek-Beckers MA, van Greevenbroek MM, Lusis AJ, de Bruin TW. Heritability and genetic loci of fatty liver in familial combined hyperlipidemia. J Lipid Res. 2006 Dec;47(12):2799-807. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004 Dec;40(6):1387-95. Brun P, Castagliuolo I, Floreani AR, Buda A, Blasone L, Palu G, Martines D. Increased risk of NASH in patients carrying the C(-159)T polymorphism in the CD14 gene promoter region. Gut. 2006 Aug;55(8):1212. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999 Sep;94(9):2467-74. Bulut Y, Faure E, Thomas L, Equils O, Arditi M. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J Immunol. 2001 Jul 15;167(2):987-94. Bydder GM, Chapman RW, Harry D, Bassan L, Sherlock S, Kreel L. Computed tomography attenuation values in fatty liver. J Comput Tomogr. 1981 Mar;5(1):33-5. Caballero F, Fernandez A, De Lacy AM, Fernandez-Checa JC, Caballeria J, Garcia-Ruiz C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol. 2009 Apr;50(4):789-96. Caldwell SH, Harris DM, Patrie JT, Hespenheide EE. Is NASH underdiagnosed among African Americans? Am J Gastroenterol. 2002 Jun;97(6):1496-500. Chan DF, Li AM, Chu WC, Chan MH, Wong EM, Liu EK, Chan IH, Yin J, Lam CW, Fok TF, Nelson EA. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord. 2004 Oct;28(10):1257-63. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E, Gavrilova O, Reitman ML. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest. 2000 Nov;106(10):1221-8. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis. 2007 Feb;11(1):37-54, viii. Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, Walajtys-Rode E, Rashid A, Chen CH, Huang CC, Wu TC, Lane MD, Diehl AM. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem. 1999 Feb 26;274(9):5692-700. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, Chen DS. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA. 1996 Sep 18;276(11):906-8. Chen W, Chang B, Li L, Chan L. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology. 2010 Sep;52(3):1134-42. Chen W, Chang MH. New growth charts for Taiwanese children and adolescents based on World Health Organization standards and health-related physical fitness. Pediatr Neonatol. 2010 Apr;51(2):69-79. Chu NF. Prevalence of obesity in Taiwan. Obes Rev. 2005 Nov;6(4):271-4. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science. 1996 Nov 15;274(5290):1185-8. Cookson S, Constantini PK, Clare M, Underhill JA, Bernal W, Czaja AJ, Donaldson PT. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology. 1999 Oct;30(4):851-6. Cowin GJ, Jonsson JR, Bauer JD, Ash S, Ali A, Osland EJ, Purdie DM, Clouston AD, Powell EE, Galloway GJ. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging. 2008 Oct;28(4):937-45. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC, Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001 Dec;34(6):1158-63. Crimmins NA, Martin LJ. Polymorphisms in adiponectin receptor genes ADIPOR1 and ADIPOR2 and insulin resistance. Obes Rev. 2007 Sep;8(5):419-23. Cui W, Chen SL, Hu KQ. Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am J Transl Res. 2010;2(1):95-104. Czaja MJ. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology. 2004 Jul;40(1):19-22. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology. 2005 Jul;129(1):375-8. Day CP, James OF. Steatohepatitis: a tale of two 'hits'? Gastroenterology. 1998 Apr;114(4):842-5. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979 Sep;237(3):E214-23. Demircioglu F, Kocyigit A, Arslan N, Cakmakci H, Hizli S, Sedat AT. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2008 Jul;47(1):68-75. Ding WX, Yin XM. Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury. J Cell Mol Med. 2004 Oct-Dec;8(4):445-54. Dixon JB, Bhathal PS, Jonsson JR, Dixon AF, Powell EE, O'Brien PE. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol. 2003 Dec;39(6):967-71. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001 Jul;121(1):91-100. Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Effect of serum albumin and bilirubin on the risk of myocardial infarction (the Framingham Offspring Study). Am J Cardiol. 2003 Feb 15;91(4):485-8. Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, Hansen T, Pedersen O. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia. 2001 Dec;44(12):2220-6. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006 Oct;44(4):865-73. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006 Feb;3(2):87-98. Esterbauer H, Oberkofler H, Linnemayr V, Iglseder B, Hedegger M, Wolfsgruber P, Paulweber B, Fastner G, Krempler F, Patsch W. Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with obesity indices in middle-aged women. Diabetes. 2002 Apr;51(4):1281-6. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11(1):81-128. Fanelli M, Filippi E, Sentinelli F, Romeo S, Fallarino M, Buzzetti R, Leonetti F, Baroni MG. The Gly482Ser missense mutation of the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) gene associates with reduced insulin sensitivity in normal and glucose-intolerant obese subjects. Dis Markers. 2005;21(4):175-80. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol. 2000 Oct;68(4):437-46. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004 Oct;40(4):820-6. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003 Aug;125(2):437-43. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009 Nov;58(11):1538-44. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009 Oct;50(4):1072-8. Fishbein MH, Miner M, Mogren C, Chalekson J. The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis. J Pediatr Gastroenterol Nutr. 2003 Jan;36(1):54-61. Flynn MA, McNeil DA, Maloff B, Mutasingwa D, Wu M, Ford C, Tough SC. Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations. Obes Rev. 2006 Feb;7 Suppl 1:7-66. Franks PW, Ekelund U, Brage S, Luan J, Schafer AJ, O'Rahilly S, Barroso I, Wareham NJ. PPARGC1A coding variation may initiate impaired NEFA clearance during glucose challenge. Diabetologia. 2007 Mar;50(3):569-73. Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC, Brunetti F, Rubino A. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci. 1997 Jul;42(7):1428-32. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995 Jun;125(6):1401-12. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006 Jan 13;124(1):35-46. Gregor MF, Yang L, Fabbrini E, Mohammed BS, Eagon JC, Hotamisligil GS, Klein S. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes. 2009 Mar;58(3):693-700. Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology. 1997 Jul;26(1):143-6. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008 Feb;47(2):455-60. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G, De La Vega FM, Briggs J, Gunther S, Prescott NJ, Onnie CM, Hasler R, Sipos B, Folsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007 Feb;39(2):207-11. Hara K, Tobe K, Okada T, Kadowaki H, Akanuma Y, Ito C, Kimura S, Kadowaki T. A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia. 2002 May;45(5):740-3. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 2003 Dec;144(12):5179-83. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008 Oct;57(10):1441-7. He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, Cohen JC, Hobbs HH. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010 Feb 26;285(9):6706-15. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, Rudolph D, Schutz G, Yoon C, Puigserver P, Spiegelman B, Montminy M. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001 Sep 13;413(6852):179-83. Heyman E, Ohlsson A, Girschek P. Retinopathy of prematurity and bilirubin. N Engl J Med. 1989 Jan 26;320(4):256. Higuchi M, Aggarwal BB, Yeh ET. Activation of CPP32-like protease in tumor necrosis factor-induced apoptosis is dependent on mitochondrial function. J Clin Invest. 1997 Apr 1;99(7):1751-8. Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, Itoh K. Polymorphism of the 5'-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens. 1998 Jun;51(6):605-12. Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenfelde KH, Rittner C. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol. 1998 Mar;54(3):173-7. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. Science. 2001 Feb 2;291(5505):881-4. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002 May;109(9):1125-31. Huang CS, Chang PF, Huang MJ, Chen ES, Chen WC. Glucose-6-phosphate dehydrogenase deficiency, the UDP-glucuronosyl transferase 1A1 gene, and neonatal hyperbilirubinemia. Gastroenterology. 2002 Jul;123(1):127-33. Huang CS, Luo GA, Huang ML, Yu SC, Yang SS. Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese. Pharmacogenetics. 2000 Aug;10(6):539-44. Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW, Huang CS. Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res. 2004 Nov;56(5):682-9. Hug H, Strand S, Grambihler A, Galle J, Hack V, Stremmel W, Krammer PH, Galle PR. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J Biol Chem. 1997 Nov 7;272(45):28191-3. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004 Jul;40(1):46-54. Hui Y, Yu-Yuan L, Yu-Qiang N, Wei-Hong S, Yan-Lei D, Xiao-Bo L, Yong-Jian Z. Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver Int. 2008 Mar;28(3):385-92. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T, Sato N. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology. 2002 May;122(5):1399-410. Inayat-Hussain SH, Couet C, Cohen GM, Cain K. Processing/activation of CPP32-like proteases is involved in transforming growth factor beta1-induced apoptosis in rat hepatocytes. Hepatology. 1997 Jun;25(6):1516-26. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology. 2006 May;43(5):1145-51. Ishizaka N, Ishizaka Y, Takahashi E, Yamakado M, Hashimoto H. High serum bilirubin level is inversely associated with the presence of carotid plaque. Stroke. 2001 Feb;32(2):580-3. Ito M, Suzuki J, Tsujioka S, Sasaki M, Gomori A, Shirakura T, Hirose H, Ishihara A, Iwaasa H, Kanatani A. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol Res. 2007 Jan;37(1):50-7. Janssen I, Katzmarzyk PT, Boyce WF, Vereecken C, Mulvihill C, Roberts C, Currie C, Pickett W. Comparison of overweight and obesity prevalence in school-aged youth from 34 countries and their relationships with physical activity and dietary patterns. Obes Rev. 2005 May;6(2):123-32. Jarvelainen HA, Orpana A, Perola M, Savolainen VT, Karhunen PJ, Lindros KO. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology. 2001 May;33(5):1148-53. Jones DE, Watt FE, Grove J, Newton JL, Daly AK, Gregory WL, Day CP, James OF, Bassendine MF. Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. J Hepatol. 1999 Feb;30(2):232-6. Kantartzis K, Peter A, Machicao F, Machann J, Wagner S, Konigsrainer I, Konigsrainer A, Schick F, Fritsche A, Haring HU, Stefan N. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes. 2009 Nov;58(11):2616-23. Kawaguchi T, Osatomi K, Yamashita H, Kabashima T, Uyeda K. Mechanism for fatty acid 'sparing' effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J Biol Chem. 2002 Feb 8;277(6):3829-35. Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 2004 Feb 15;18(4):357-68. Kienesberger PC, Oberer M, Lass A, Zechner R. Mammalian patatin domain containing proteins: a family with diverse lipolytic activities involved in multiple biological functions. J Lipid Res. 2009 Apr;50 Suppl:S63-8. Kinugasa A, Tsunamoto K, Furukawa N, Sawada T, Kusunoki T, Shimada N. Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gastroenterol Nutr. 1984 Jun;3(3):408-14. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313-21. Knutti D, Kaul A, Kralli A. A tissue-specific coactivator of steroid receptors, identified in a functional genetic screen. Mol Cell Biol. 2000 Apr;20(7):2411-22. Kollerits B, Coassin S, Kiechl S, Hunt SC, Paulweber B, Willeit J, Brandstatter A, Lamina C, Adams TD, Kronenberg F. A common variant in the adiponutrin gene influences liver enzyme values. J Med Genet. 2010 Feb;47(2):116-9. Kotronen A, Johansson LE, Johansson LM, Roos C, Westerbacka J, Hamsten A, Bergholm R, Arkkila P, Arola J, Kiviluoto T, Fisher RM, Ehrenborg E, Orho-Melander M, Ridderstrale M, Groop L, Yki-Jarvinen H. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia. 2009 Jun;52(6):1056-60. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstrale M, Groop L, Orho-Melander M, Yki-Jarvinen H. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009 Sep;137(3):865-72. Kotronen A, Yki-Jarvinen H, Aminoff A, Bergholm R, Pietilainen KH, Westerbacka J, Talmud PJ, Humphries SE, Hamsten A, Isomaa B, Groop L, Orho-Melander M, Ehrenborg E, Fisher RM. Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. Eur J Endocrinol. 2009 Apr;160(4):593-602. Lancaster JR, Jr., Laster SM, Gooding LR. Inhibition of target cell mitochondrial electron transfer by tumor necrosis factor. FEBS Lett. 1989 May 8;248(1-2):169-74. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000 Jun;136(6):734-8. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000 Apr;105(8):1067-75. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, Dargel R, Poli G. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor beta1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J. 1997 Sep;11(11):851-7. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saffitz JE, Abel ED, Semenkovich CF, Kelly DP. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 2005 Apr;3(4):e101. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006 Dec 21;444(7122):1022-3. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003 Feb;37(2):343-50. Limanond P, Raman SS, Lassman C, Sayre J, Ghobrial RM, Busuttil RW, Saab S, Lu DS. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology. 2004 Jan;230(1):276-80. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005 Jun;1(6):361-70. Lin J, Tarr PT, Yang R, Rhee J, Puigserver P, Newgard CB, Spiegelman BM. PGC-1beta in the regulation of hepatic glucose and energy metabolism. J Biol Chem. 2003 Aug 15;278(33):30843-8. Lin J, Yang R, Tarr PT, Wu PH, Handschin C, Li S, Yang W, Pei L, Uldry M, Tontonoz P, Newgard CB, Spiegelman BM. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell. 2005 Jan 28;120(2):261-73. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, Yang S, Kronenberg F. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation. 2006 Oct 3;114(14):1476-81. Lin YC, Chang PF, Hu FC, Chang MH, Ni YH. Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. Pediatrics. 2009 Dec;124(6):e1221-7. Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH. A Common Variant in the PNPLA3 Gene is a Risk Factor for Non-Alcoholic Fatty Liver Disease in Obese Taiwanese Children. J Pediatr. 2010 Dec 17. Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S11-6. Liu YM, Moldes M, Bastard JP, Bruckert E, Viguerie N, Hainque B, Basdevant A, Langin D, Pairault J, Clement K. Adiponutrin: A new gene regulated by energy balance in human adipose tissue. J Clin Endocrinol Metab. 2004 Jun;89(6):2684-9. Loomba R, Hwang SJ, O'Donnell CJ, Ellison RC, Vasan RS, D'Agostino RB, Sr., Liang TJ, Fox CS. Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study. Gastroenterology. 2008 Apr;134(4):953-9. Loomba R, Wesley R, Pucino F, Liang TJ, Kleiner DE, Lavine JE. Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. Clin Gastroenterol Hepatol. 2008 Nov;6(11):1243-8. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980 Jul;55(7):434-8. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002 Jul;8(7):731-7. Malaguarnera L, Madeddu R, Palio E, Arena N, Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepatol. 2005 Apr;42(4):585-91. Manco M, Marcellini M, Giannone G, Nobili V. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol. 2007 Jun;127(6):954-60. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab. 2005 Aug;90(8):4542-8. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999 Nov;107(5):450-5. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003 Apr;37(4):917-23. Mari M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC, Garcia-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 2006 Sep;4(3):185-98. Massey DC, Parkes M. Genome-wide association scanning highlights two autophagy genes, ATG16L1 and IRGM, as being significantly associated with Crohn's disease. Autophagy. 2007 Nov-Dec;3(6):649-51. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999 Jun;116(6):1413-9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 2002 Mar;34(3):255-62. Miele L, Beale G, Patman G, Nobili V, Leathart J, Grieco A, Abate M, Friedman SL, Narla G, Bugianesi E, Day CP, Reeves HL. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology. 2008 Jul;135(1):282-91 e1. Molleston JP, White F, Teckman J, Fitzgerald JF. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol. 2002 Sep;97(9):2460-2. Moran JR, Ghishan FK, Halter SA, Greene HL. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol. 1983 Jun;78(6):374-7. Musso G, Gambino R, De Michieli F, Durazzo M, Pagano G, Cassader M. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. Hepatology. 2008 Apr;47(4):1167-77. Namikawa C, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, Akisawa N, Saibara T, Hiroi M, Enzan H, Onishi S. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol. 2004 May;40(5):781-6. Neimark E, LeLeiko NS. Antioxidant effect of bilirubin and pediatric nonalcoholic fatty liver disease. Pediatrics. 2009 Dec;124(6):e1240-1. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010 Aug;52(2):774-88. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003 May;37(5):1202-19. Ni YH, Chang MH, Chen PJ, Tsai KS, Hsu HY, Chen HL, Tsuei DJ, Chen DS. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology. 2007 Jun;132(7):2340-5. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, Tsai KS, Chen DS. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001 Nov 6;135(9):796-800. Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, Marcellini M, Marchesini G. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther. 2008 Jun;30(6):1168-76. Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006 Dec;24(11-12):1553-61. Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/48140 | - |
dc.description.abstract | 非酒精性脂肪肝疾病的範疇包含從單純性肝臟脂肪堆積到潛在有致死性風險的非酒精性脂肪肝炎,甚至是已經到達肝硬化的程度。隨著兒童肥胖逐漸盛行,非酒精性脂肪肝疾病是愈來愈惡化的全球性兒童青少年健康問題。雖然非酒精性脂肪肝疾病是全世界造成慢性肝病的最常見原因,但是其致病機轉仍然不明。肥胖是非酒精性脂肪肝疾病發生的最重要危險因子,會引起胰島素抗拒。然而不是所有肥胖兒童都會發生非酒精性脂肪肝疾病,這表示其他環境與基因遺傳因子對於非酒精性脂肪肝疾病的易感受性與是否會惡化具有決定性的關鍵影響。
有關非酒精性脂肪肝疾病的致病機轉,Day等人於1998年提出雙擊假說,第一擊是肝臟內脂肪的過度堆積,與胰島素抗拒有關。經過第一擊後的肝臟細胞會容易受第二擊的影響,使得肝臟細胞受損、發炎與纖維化。第二擊是由於脂肪過度氧化產生的氧化壓力與細胞激素造成傷害。我們選擇候選基因的原則也是基於雙擊理論中對第一擊與第二擊具有重要影響力的基因。 對於第一擊部分, Patalin-like phospholipase (PNPLA3)與脂肪細胞內三酸甘油酯的水解有關,對於非酒精性脂肪肝疾病第一擊致病過程有重要影響。Romeo等人首先報告PNPLA3 rs738409單一核甘酸多型性在成人與肝臟脂肪堆積的嚴重度有很強的相關性。我們假說PNPLA3 rs738409 G對偶基因會增加在肥胖兒童中發生非酒精性脂肪性肝疾病的危險性。我們收案520名6到18歲的肥胖兒童青少年,以肝臟超音波評估是否有非酒精性脂肪性肝疾病,同時測量他們的肝功能指數血清ALT值,並鑑定PNPLA3 rs738409單一核甘酸多型性為CC、CG或是GG基因型。以多變量邏輯迴歸分析與線性迴歸分析分別檢定PNPLA3 rs738409單一核甘酸多型性對於兒童非酒精性脂肪肝疾病與血清ALT值的影響。我們發現19.6%的肥胖兒童青少年有非酒精性脂肪肝疾病。相較於PNPLA3 rs738409 CC野生基因型,CG基因型增加了2.96倍發生非酒精性脂肪肝疾病的危險性(95%信賴區間:157-5.59;P = 0.0008);GG基因型甚至增加了5.84倍發生非酒精性脂肪肝疾病的危險性(95%信賴區間:2.59-13.16;P < 0.0001)。另外,相較於PNPLA3 rs738409 CC野生基因型,CG基因型組的平均血清ALT值增加了4.77 IU/L (P = 0.0435);GG基因型組的平均血清ALT值增加了10.86 IU/L (P < 0.0001)。總結來說,對於台灣地區肥胖兒童,PNPLA3 rs738409單一核甘酸多型性基因變異增加了發生非酒精性脂肪肝疾病的危險性。由於PNPLA3 rs738409 同型合子GG基因型增加非酒精性脂肪肝疾病的危險性為異型合子CG基因型所增加的2倍,表示PNPLA3 rs738409 G對偶基因對非酒精性脂肪肝疾病的影響效應為顯性遺傳模式。 對於第二擊部分,氧化壓力扮演非酒精性脂肪肝疾病第二擊致病過程中很重要的角色。膽紅素具有抗氧化的功能,而UGT1A1基因的變異是影響膽紅素濃度的主要因素。在第一部分研究,我們假說UGT1A1基因變異會減少非酒精性脂肪肝疾病的發生。我們收案了234名6到13歲的肥胖兒童,以肝臟超音波評估是否有非酒精性脂肪肝疾病。UGT1A1基因型,包括UGT1A1*6與UGT1A1*28,以聚合酶連鎖反應-限制酶片段長度多型性方法來鑑定。以多變量邏輯迴歸分析檢定UGT1A1基因變異對於兒童非酒精性脂肪性肝疾病發生的影響。我們發現12%肥胖兒童受試者有非酒精性脂肪肝疾病。相較於沒有非酒精性脂肪肝疾病組,非酒精性脂肪肝疾病組的血清總膽紅素值組顯著為低(0.36 ± 0.38 mg/dL vs. 0.25 ± 0.30 mg/dL;P = 0.021)。於控制了身體質量指數、腰臀圍比與adiponectin值的效應後,UGT1A1*6基因變異為兒童非酒精性脂肪肝疾病的一項獨立顯著性保護因子,勝算比為0.31 (95%信賴區間:0.11-0.91;P = 0.033)。至於UGT1A1*28基因變異則與我們受試者的非酒精性脂肪肝疾病沒有顯著相關性。總結來說,對於台灣地區肥胖兒童,UGT1A1*6基因變異減少了發生非酒精性脂肪肝疾病的危險性。UGT1A1基因型是對於兒童非酒精性脂肪肝疾病發生的一個新影響因子。 根據文獻上家族集簇性研究顯示兒童非酒精性脂肪肝疾病的遺傳性很高。因此,我們分析與非酒精性脂肪肝疾病致病過程第一擊與第二擊有重要相關的11個候選基因中的24個單一核甘酸多型性,在控制了PNPLA3 rs738409基因型的干擾因素後,以多變量邏輯迴歸分析檢定這些單一核甘酸多型性基因變異對於兒童非酒精性脂肪肝疾病的影響。挑選的候選基因,包括了自體吞噬途徑上的ATG16L1、 PIK3C3及 IRGM;類鐸受體途徑上的TOLLIP及CD14;發炎反應途徑上的TNF-α;脂肪酸代謝途徑上的PPARG及PPARGC1A;與adiponectin訊息傳導途徑上的ADIPOQ、ADIPOR1及ADIPOR2。這些單一核甘酸多型性在華人漢族中的少數對偶基因頻率至少要大於5%。我們總共挑選出95名有非酒精性脂肪肝疾病的個案組與91名沒有非酒精性脂肪肝疾病的控制組。在控制了腰圍、三酸甘油酯、adiponectin值與PNPLA3 rs738409 GG基因型等干擾因子後,PPARGC1A rs8192678基因變異顯著地增加了發生兒童非酒精性脂肪肝疾病的危險性(勝算比:2.21;95%信賴區間:1.04-4.69;P = 0.0389);TNF-α rs1799964基因變異則顯著地減少了發生兒童非酒精性脂肪肝疾病的危險性(勝算比:0.49;95%信賴區間:0.24-0.99;P = 0.0487)。我們進一步分析所有520名受試者的PPARGC1A rs8192678單一核甘酸多型性基因型,於控制PNPLA3 rs738409基因變異型後,相較於野生基因型,PPARGC1A rs8192678基因變異型增加了1.90倍發生非酒精性脂肪肝疾病的危險性(95%信賴區間1.02-3.57;P = 0.045)。總結來說,對於台灣地區肥胖兒童,PPARGC1A rs8192678單一核甘酸多型性基因變異與TNF-α rs1799964單一核甘酸多型性基因變異會獨立顯著性地影響發生非酒精性脂肪肝疾病發生的危險性。 另外,非酒精性脂肪肝疾病病患的肝臟組織檢體會有較高的膽固醇堆積。相對於單純性肝臟脂肪堆積病患,非酒精性脂肪肝炎病患會有更高的肝臟組織內膽固醇堆積。這結果顯示肝臟膽固醇過度堆積對於非酒精性脂肪肝疾病的第二擊致病過程有重要影響。我們以油酸引發的Huh7脂肪肝細胞模式來探討肝臟細胞脂肪堆積影響膽固醇代謝異常的致病機轉。我們發現膽固醇新生合成關鍵酵素HMG-CoA reductase的訊息核醣核酸表現量,與控制組相較,在0.5 mM油酸組增加19%基因表現量(P = 0.024)。HMG-CoA reductase是膽固醇新生合成的速率決定酵素,增加HMG-CoA reductase基因表現量會導致肝臟細胞增加膽固醇合成。我們的實驗結果顯示脂肪肝細胞內過多的膽固醇堆積可能是連結非酒精性脂肪肝疾病第一擊與第二擊致病過程的重要分子因素。 我們的研究結果將有助於進一步了解影響台灣地區肥胖兒童發生非酒精性脂肪肝疾病的重要基因遺傳因子。由於文獻報告上極少有亞洲裔兒童的相關基因資料,因此我們的研究成果對於全球性分析不同種族間發生非酒精性脂肪肝疾病的基因遺傳因子,像是比較西班牙裔、非洲裔、北美或是歐洲裔白人等,具有重要的學術價值。 | zh_TW |
dc.description.abstract | Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of conditions ranging from simple hepatic steatosis to potentially fatal nonalcoholic steatohepatitis and cirrhosis. Concurrent with the epidemic of childhood obesity, pediatric NAFLD is a growing global problem. The pathogenesis of NAFLD is multifactorial; it is strongly associated with obesity and insulin resistance. Not all children with obesity will develop NAFLD, suggesting that genetic factors may contribute to the NAFLD susceptibility.
NAFLD is a complex metabolic disease that is strongly associated with obesity and insulin resistance. Day and James proposed a two-hit hypothesis. Fat accumulation in the liver is the first hit. Additional hits, including oxidative stress, lipotoxicity, adipocytokines, etc., are potential mediators in inducing persistent liver injury. Candidate genes studied in our studies were selected based on the two-hit hypothesis. With regard to the genetic susceptibility to the first hit, PNPLA3 rs738409 single nucleotide polymorphism (SNP), causing a nonsynonymous sequence variation I148M, had a strong association with increased liver fat content in adults. In our study, we hypothesized that the presence of the PNPLA3 rs738409 G allele would increase the susceptibility of NAFLD in obese Taiwanese children. We recruited a total of 520 obese children aged 6-18 years. Their PNPLA3 rs738409 genotypes-CC, CG, or GG-were detected by the 5'-nuclease assay. The effects of the PNPLA3 rs738409 G allele on pediatric NAFLD were evaluated based on liver ultrasonography findings and mean serum alanine aminotransferase levels in these children. We found that NAFLD was present in 19.6% of the obese children. In comparison to the subjects with CC alleles, the risk of NAFLD was increased by 2.96-fold (95% confidence interval, 1.57-5.59, P = 0.0008) in the subjects with CG alleles and by 5.84-fold (95% confidence interval, 2.59-13.16; P < 0.0001) in those with GG alleles. Variant PNPLA3 rs738409 genotypes were associated with increases in mean serum alanine aminotransferase level of 4.77 IU/L (P = 0.0435) in subjects with CG alleles and of 10.86 IU/L (P < 0.0001) in those with GG alleles compared with subjects with CC alleles. In conclusion, the variant PNPLA3 rs738409 genotypes increased the risk of NAFLD in our population of obese Taiwanese children. The effect of the G allele on pediatric NAFLD followed a dominant genetic model. With regard to the genetic susceptibility to the second hit, oxidative stress plays an important role in the pathogenesis of NAFLD. Variants in the UGT1A1 gene contribute to increased bilirubin levels, and bilirubin can act as an antioxidant. In our study, we hypothesized that variant UGT1A1 genotypes would reduce the risk for NAFLD development. We recruited 234 obese children 6 to 13 years of age. NAFLD was determined through liver ultrasonography. The UGT1A1 genotypes UGT1A1*6 and UGT1A1*28 were detected. We assessed the effects of UGT1A1 genotypes on pediatric NAFLD. We found that in total, 12% of the obese children had NAFLD. The subjects with NAFLD had lower serum total bilirubin levels (0.25 ± 0.30 mg/dL) than did those without NAFLD (0.36 ± 0.38 mg/dL; P = 0.021). With conditioning on the effects of age- and gender-adjusted BMI, waist/hip ratio, and adiponectin levels, variant UGT1A1*6 genotypes were a protecting factor for NAFLD, with an estimated adjusted odds ratio (OR) of 0.31 [95% confidence interval (CI): 0.11-0.91; P = 0.033], but variant UGT1A1*28 genotypes were not significantly associated with the occurrence of NAFLD. In conclusion, variant UGT1A1*6 genotypes are associated with a lower risk of NAFLD in obese Taiwanese children. The UGT1A1 genotype is a new risk factor for pediatric NAFLD. The heritability of pediatric NAFLD, as estimated by family aggregation study, is high. We genotyped 24 selected SNPs in 11 NAFLD-related candidate genes which may be involved in the first hit or second hit on the pathogenesis of NAFLD . We examined the associations between SNPs and the risk of pediatric NAFLD in obese children with conditioning on the effect of PNPLA3 rs738409 polymorphism. We selected these 24 SNPs by a pathway-driven approach, including autophagy (ATG16L1, PIK3C3, IRGM), toll-like receptor (CD14, TOLLIP), inflammatory (TNF-α), fatty acid metabolism (PPARG, PPARGC1A), and adiponectin signaling (ADIPOQ, ADIPOR1, ADIPOR2) pathways. SNPs were chosen based on minor allele frequency higher than 5% among Han Chinese. NAFLD was determined by liver ultrasonography. Associations between SNPs and pediatric NAFLD were examined using multiple logistic regression models. We found that a total of 95 cases and 91 controls were studied. The two groups matched each other in terms of age, gender and body mass index. With conditioning on the effects of waist circumference, triglyceride, adiponectin and PNPLA3 rs738409 polymorphism, one PPARGC1A SNP (rs8192678) was significantly associated with an increased risk for pediatric NAFLD OR, 2.21; 95% CI, 1.04–4.69; P=0.0389) and one TNF-α SNP (rs1799964) was significantly associated with a decreased risk for pediatric NAFLD (OR, 0.49; 95% CI, 0.24–0.99; P=0.0487). We further genotyped all 520 participants and analyzed the effect of PPARGC1A rs8192678 SNP variants on pediatric NAFLD. With conditioning on the effects of gender, adujsted BMI, waist circumference, adiponectin and PNPLA3 rs738409 polymorphism, variant PPARGC1A rs819267 genotypes increased the risk for pediatric NAFLD by 90% (OR, 1.9; 95% CI, 1.02–3.57; P=0.045). In conclusion, the variant PPARGC1A rs8192678 and TNF-α rs1799964 genotypes significantly modified the risk of NAFLD independent of the effect of PNPLA3 rs738409 polymorphism in our population of obese Taiwanese children. Excessive cholesterol accumulation in the liver is involved in the deterioration of NAFLD. The underlying mechanism was unknown. We used an oleic acid-induced steatotic Huh7 cell model to investigate the changes in the expression levels of key cholesterol metabolism genes. We found that the mRNA expression of HMG-CoA reductase was increased by 19% in 0.5 mM oleic acid treated steatotic Huh7 cells (P = 0.024). HMG-CoA reductase is the rate-limiting key enzyme in the regulation of cholesterol biosynthesis in liver. We proved that the excessive cholesterol accumulation in the NAFLD liver is induced by increased expression of HMG-CoA reductase gene. Our results suggest that cholesterol is a possible lipid mediator linking the first hit and the second hit on the pahtogenesis of NAFLD. In summary, we focused on finding associations between pediatric NAFLD and variants in candidate genes encoding proteins involved in NAFLD pathogenesis. Our findings may contribute to the understanding of the genetic susceptibility to pediatric NAFLD. Considering the lack of data in Asian children, the results of our genetic association studies in obese Taiwanese children could be valuable for global comparisons with data from other ethnic groups, including Hispanic, African, and North American or European origin. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T06:47:10Z (GMT). No. of bitstreams: 1 ntu-100-Q92421006-1.pdf: 1930424 bytes, checksum: 5beb3cd5d0fa5ecd90225237c0dccb93 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 論文口試委員會審定書 ………………………………………… i
誌謝 ……………………………………………………………… ii 中文摘要 ………………………………………………………… iii 英文摘要 ………………………………………………………… vi 目錄 ……………………………………………………………… ix 圖目錄 …………………………………………………………… x 表目錄 …………………………………………………………… xi 博士論文內容 第一章 緒論 …………………………………………………… 1 第二章 研究方法與材料 ……………………………………… 23 第三章 結果 …………………………………………………… 35 第四章 討論 …………………………………………………… 49 第五章 展望 …………………………………………………… 72 第六章 論文英文簡述 ………………………………………… 84 第七章 參考文獻 ……………………………………………… 113 第八章 圖表 …………………………………………………… 141 第九章 附錄 …………………………………………………… 180 | |
dc.language.iso | zh-TW | |
dc.title | 遺傳基因於肥胖兒童非酒精性脂肪肝疾病的影響 | zh_TW |
dc.title | Genetic Influences in Non-alcoholic Fatty Liver Disease in Obese Children | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 倪衍玄(Yen-Hsuan Ni) | |
dc.contributor.oralexamcommittee | 楊偉勛(Wei-Shiung Yang),吳子聰(Tzee-Chung Wu),黃國晉(Kuo-Chin Huang),曾明淑(Min-Su Tzeng) | |
dc.subject.keyword | 兒童,非酒精性脂肪肝疾病,單一核甘酸多型性,UGT1A1,PNPLA3,PPARGC1A,TNF-α,膽固醇,脂肪肝細胞模式,HMG-CoA reductase, | zh_TW |
dc.subject.keyword | children,non-alcoholic fatty liver disease,UGT1A1,PNPLA3,PPARGC1A,TNF-α,cholesterol,steatotic cell model,HMG-CoA reductase, | en |
dc.relation.page | 181 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-06-14 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 1.89 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。